Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Status:
Not yet recruiting
Trial end date:
2032-04-01
Target enrollment:
Participant gender:
Summary
Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy.
An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to
adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and
may also receive involved site radiotherapy as consolidation.
Patients will be followed up for a minimum of 5 years after treatment.